Cancer surveillance should be adopted, not just for CS/PHTS patients (with or without PTEN mutation), but also for patients with demonstrated PTEN mutation but not fulfilling CS diagnostic criteria. Here, PTEN is linked to PTEN hamartoma tumor syndrome.